Irritable Bowel Syndrome: Causes, Symptoms And Remedy

Losartanphenobarbital will decrease the extent or impact of losartan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Loratadinephenobarbital will decrease the extent or impact of loratadine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lopinavirphenobarbital will decrease the level or effect of lopinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Loperamidephenobarbital will decrease the level or effect of loperamide by P-glycoprotein efflux transporter.

Acetaminophen rectalphenobarbital decreases ranges of acetaminophen rectal by rising metabolism. Acetaminophen IVphenobarbital decreases ranges of acetaminophen IV by rising metabolism. Acetaminophenphenobarbital decreases ranges of acetaminophen by increasing metabolism. Thalidomidethalidomide will increase results of phenobarbital by unspecified interaction mechanism. Sorafenibphenobarbital decreases ranges of sorafenib by growing metabolism. Rufinamidephenobarbital decreases ranges of rufinamide by increasing metabolism.

Caution with sensitive CYP2C19 substrates. Phenobarbital and droperidol each enhance sedation. Phenobarbital and doxylamine each noxema for sunburns increase sedation.

Phenobarbital will decrease the extent or effect of estrogens conjugated artificial by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the level or effect of estradiol vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the level or impact of estradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will lower the level or effect of esomeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the extent or impact of escitalopram by affecting hepatic enzyme CYP2C19 metabolism.

Phenobarbital will lower the level or effect of sofosbuvir/velpatasvir by P-glycoprotein efflux transporter. Sofosbuvir and velpatasvir are substrates of the drug transporter P-gp. Potent P-gp inducers may considerably decrease sofosbuvir and velpatasvir plasma concentrations, resulting in probably lowered therapeutic effect. Phenobarbital will decrease the extent or effect of guanfacine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Strong or average CYP3A4 inducers considerably reduce guanfacine plasma concentrations and elimination half-life. If coadministered, extra frequent dosing of the IR product could also be required to attain or preserve the specified hypotensive response.

Apalutamide will lower the extent or effect of phenobarbital by affecting hepatic enzyme CYP2C19 metabolism. Coadministration of apalutamide, a strong CYP2C19 inducer, with drugs which are CYP2C19 substrates can lead to lower exposure to these drugs. Avoid or substitute another drug for these medications when possible. Evaluate for lack of therapeutic effect if treatment must be coadministered. Osilodrostatphenobarbital will lower the extent or impact of osilodrostat by Other .

Coadministration with a robust CYP3A inducer decreases duvelisib area underneath the curve , which can reduce duvelisib efficacy. Phenobarbital will decrease the extent or impact of dienogest/estradiol valerate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the level or impact of diazepam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Strong or moderate CYP3A4 inducers might increase fee of diazepam elimination; subsequently, efficacy of diazepam could also be decreased.